Metastatic Ovarian Cancer - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape.

Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 9 and 2 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Metastatic Ovarian Cancer.

Metastatic Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Ovarian Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Ovarian Cancer - Overview 9
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis 10
Metastatic Ovarian Cancer - Therapeutics under Development by Companies 11
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Ovarian Cancer - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Ovarian Cancer - Products under Development by Companies 15
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes 16
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development 17
Adgero Biopharmaceuticals Inc 17
Cellceutix Corporation 18
Eisai Co., Ltd. 19
F. Hoffmann-La Roche Ltd. 20
Immune Design Corp. 21
Millennium Pharmaceuticals Inc 22
MolMed S.p.A. 23
Natco Pharma Limited 24
Northwest Biotherapeutics, Inc. 25
Pfizer Inc. 26
Richter Gedeon Nyrt. 27
Sumitomo Dainippon Pharma Co., Ltd. 28
VG Life Sciences, Inc. 29
Metastatic Ovarian Cancer - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
Antisense RNAi Oligonucleotide to Replace MicroRNA-138 for Metastatic Ovarian Cancer - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
bevacizumab biosimilar - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CMB-305 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
crizotinib - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
DCVax-Direct - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
DCVax-L - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
E-7449 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
emactuzumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
G-305 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
gedatolisib - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
hydroxychloroquine + sorafenib tosylate - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Kevetrin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
LV-305 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
NGR-hTNF - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
NRCAN-019 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
orteronel - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
OS-2966 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
REM-001 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
SM-276001 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Vaccine for Oncology - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Metastatic Ovarian Cancer - Dormant Projects 101
Metastatic Ovarian Cancer - Discontinued Products 102
Metastatic Ovarian Cancer - Product Development Milestones 103
Featured News & Press Releases 103
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

List of Tables

Number of Products under Development for Metastatic Ovarian Cancer, H2 2016 9
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Metastatic Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 17
Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2016 18
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2016 19
Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 20
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2016 21
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 22
Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2016 23
Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2016 24
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2016 25
Metastatic Ovarian Cancer - Pipeline by Pfizer Inc., H2 2016 26
Metastatic Ovarian Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 27
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 28
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Metastatic Ovarian Cancer - Dormant Projects, H2 2016 101
Metastatic Ovarian Cancer - Discontinued Products, H2 2016 102